Table 1. Clinical characteristics of five subjects treated with plasma exchange

Subject number		No. 1	No. 2	No. 3	No. 4	No. 5
Age (months)		58.08	66.56	38.83	53.55	25.56
Clinical presentation		Complete	Complete	Complete	Complete	Complete
Recurrent illness		Yes (5mo)	No	No	No	No
Tx (fever day)	1^st	IVIG (D5)	IVIG (D6)	IVIG (D5)	IVIG (D6)	IVIG (D4)
	2^nd	IVIG (D8)	IVIG+mPD (D7)	IVIG+mPD (D8)	IVIG+mPD (D10)	IVIG (D6)
	3^rd	mPD (D9)	PE (D14)	PE (D14)	Infliximab (D14)	mPD (D9)
	4^th	Infliximab (D14)			PE (D15)	PE (D13)
	5^th	PE (D16)
CAA (mm (z score))	Pre-IVIG	Normal	Normal	Normal	Normal	Normal
	Post-IVIG	Normal				Normal
	Pre-PE	AN (D14)LAD (3.06(2.63))	AN (D14)RCA (4.13(3.31))	Normal	AN (D14)LAD (6.2(6.56))LMCA (4.47(3.90)RCA (4.1(3.58))	Normal
	Follow up <3 month	ANLAD (6.25(6.56))GARCA (9(7.47))	Resolved	Normal	ANLMCA (3.6(2.55))RCA (3.1(2.68))GA	Normal
	Follow up 1 year	ANLAD (4.6(4.62))GARCA (9.3(7.42))	Normal	Normal	LAD (8.2(6.98)) ResolvedLMCA, RCAGALAD (8.7(8.16))	Normal

Tx: treatment; IVIG: intravenous immunoglobulin; mPD: methyl prednisolone; PE: plasma exchange; CAA: coronary artery abnormality; LMCA: left main coronary artery; LAD: left anterior descending coronary artery; RCA: right coronary artery; AN: aneurysm; GA: giant aneurysm.